Results from the world’s largest prospective artificial intelligence study revealed the system could significantly benefit breast cancer screening programs.

In some cases, the method even helps to home in on sentinel nodes that may not have been identified during prior biopsy.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Use of the new tracer could improve outcomes by enabling providers to adjust treatment regimens much earlier than they have been able to previously. 

Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 44% if caught early, dropping down to 3% if it metastasizes. This is largely due to its ability to elude detection.

The CDC estimates that over 6 million people in the U.S. struggle with OUD, and prior research has indicated that only 20% receive treatment for the disorder.

Patients with asymmetries on CEM typically are recalled for additional views, ultrasound and occasionally MRI. But the extra workup might not be necessary.

The methods enable providers to identify signs of sepsis by assessing blood flow throughout the muscles.